2. Next Generation Multispecific Antibody Current Clinical Development & Future Commercialization Outlook
2.1 Current Market Overview
2.2 Future Commercialization Opportunity
2.3 Collaborations, License Agreements, Investments & Acquisitions
2.4 Next Generation Multispecific Antibody Proprietary Technologies By Company
3. Next Generation Multispecific Antibody Clinical Trends by Indication
3.1 Cancer
3.2 Hematological Disorders
3.3 Microbial Infections
3.4 Autoimmune & Inflammatory Disorders
3.5 Ocular Diseases
4. Next Generation Multispecific Antibody Clinical Development & Market Trends by Region
4.1 US
4.2 EU
4.3 China
4.4 UK
4.5 Japan
4.6 Australia
4.7 South Korea
4.8 Canada
5. Approved Multispecific Antibodies - Clinical Overview, Pricing & Dosage Insight
5.1 Overview
5.2 Clinical Overview, Pricing & Dosage Insight
8. Global Bispecific Antibodies Clinical Trials By Company, Indication & Phase
8.1 Research
8.2 Preclinical
8.3 Phase-I
8.4 Phase-I/II
8.5 Phase-II
8.6 Phase-II/III
8.7 Phase-III
8.8 Preregistration
8.9 Registered
10. Global Trispecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase
10.1 Research
10.2 Preclinical
10.3 Phase I
10.4 Phase I/II
10.5 Phase II/III
11. Tetraspecific Antibodies Clinical Trials Insight By Company, Country, Indication & Phase
11.1 Preclinical
11.2 Phase I
11.3 Phase I/II
11.4 Phase II
12. Competitive Landscape
12.1 AbbVie
12.2 ABL Bio
12.3 Abzyme Therapeutics
12.4 Affimed Therapeutics
12.5 Akeso Biopharma
12.6 Alligator Bioscience
12.7 Amgen
12.8 Antibody Therapeutics
12.9 APITBIO
12.10 Astellas Pharma
12.11 AstraZeneca
12.12 Aptevo Therapeutics
12.13 BioAtla
12.14 Biocytogen Pharmaceuticals
12.15 Biosion
12.16 EpimAb Biotherapeutics
12.17 FutureGen Biopharmaceutical
12.18 Genentech
12.19 Genmab
12.20 Genor Biopharma
12.21 Gensun Biopharma
12.22 Harbour BioMed
12.23 IGM Biosciences
12.24 I-MAB Biopharma
12.25 ImmuneOnco Biopharma
12.26 ImmunoPrecise Antibodies
12.27 Innate Pharma
12.28 Innovent Biologics
12.29 Invenra
12.30 Johnson & Johnson
12.31 Kenjockety Biotechnology
12.32 LaNova Medicines Limited
12.33 Light Chain Bioscience
12.34 Linton Pharm
12.35 Lyvgen Biopharma
12.36 MacroGenics
12.37 Merck
12.38 Merus
12.39 ModeX Therapeutics (OPKO Health)
12.40 Molecular Partners
12.41 NovaRock Biotherapeutics
12.42 Numab
12.43 OPKO Health
12.44 Pfizer
12.45 Regeneron Pharmaceuticals
12.46 Revitope
12.47 Roche
12.48 Sanofi
12.49 Sichuan Baili Pharmaceutical
12.50 SystImmune
12.51 Virtuoso Therapeutics
12.52 Xencor
12.53 Y-Biologics
12.54 Zhejiang Shimai Pharmaceutical
12.55 Zymeworks
List of Tables
Table 2-1: Estimated Total Cancer Cases, 2022 & 2040
Table 2-2: Multispecific Antibodies Under Regulatory Review
Table 3-1: Hematological Cancers - Approved Multispecific Antibodies
Table 3-2: Hematological Malignancies - Estimated Total Cancer Cases, 2022 & 2040
Table 3-3: Solid Cancers - Approved Multispecific Antibodies
Table 3-4: Solid Cancers - Estimated Total Cancer Cases, 2022 & 2040
Table 4-1: US - Multispecific Antibodies in Clinical Trials
Table 4-2: EU - Multispecific Antibodies in Clinical Trials
Table 4-3: UK - Multispecific Antibodies in Clinical Trials
Table 4-4: Japan - Multispecific Antibodies in Clinical Trials
Table 4-5: Australia - Multispecific Antibodies in Clinical Trials
Table 4-6: South Korea - Multispecific Antibodies in Clinical Trials
Table 4-7: Canada - Multispecific Antibodies in Clinical Trials
Table 5-1: Approved Multispecific Antibodies
Table 5-2: Blincyto - Active Patents
Table 5-3: Blincyto - Recommended Dosage & Schedule for the Treatment of MRD-positive B-cell Precursor ALL
Table 5-4: Blincyto - Recommended Dosage & Schedule for Treatment of Relapsed or Refractory B-cell Precursor ALL
Table 5-5: Blincyto - Recommended Dosage & Schedule for Treatment of Relapsed or Refractory B-cell Precursor ALL
Table 5-6: Rybrevant - Premedication
Table 5-7: Rybrevant - Dose Reductions for Adverse Reactions
Table 5-8: Rybrevant - Recommended Dosage Modifications for Adverse Reactions
Table 5-9: Lunsumio - Recommended Treatment Cycles
Table 5-10: Lunsumio - Recommended Premedications
Table 5-11: Lunsumio - Recommendations for Management of Cytokine Release Syndrome
Table 5-12: Tecvayli - Dosing Schedule
Table 5-13: Tecvayli - Recommended Dosage Modifications for Adverse Reactions
Table 5-14: Columvi - Dosing Schedule (21-Day Treatment Cycles)
Table 5-15: Columvi - Premedications to be Administered
Table 5-16: Columvi - Recommendations for Management of Cytokine Release Syndrome
Table 5-17: Columvi - Recommended Dosage Modification for Neurologic Toxicity (Including ICANS)
Table 5-18: Columvi - Recommended Dosage Modifications for Other Adverse Reactions
Table 5-19: Epkinly - Dosage Schedule
Table 5-20: Epkinly - Recommendations for Management of Cytokine Release Syndrome
Table 5-21: Epkinly - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Table 5-22: Epkinly - Recommended Dosage Modifications for Other Adverse Reactions
Table 5-23: Talvey - Weekly Dosing Schedule
Table 5-24: Talvey - Biweekly Dosing Schedule
Table 5-25: Talvey - Recommendations for Management of CRS
Table 5-26: Talvey - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Table 5-27: Talvey - Recommendations for Management of Neurologic Toxicity (excluding ICANS)
Table 5-28: Talvey - Recommended Dosage Modifications for Other Adverse Reactions
Table 5-29: Elrexfio - Dosing Schedule
Table 5-30: Elrexfio - Recommendations for Management of CRS
Table 5-31: Elrexfio - Recommended Dosage Modifications for Other Adverse Reactions
Table 5-32: Kaitani - Recommended Dose modifications
Table 5-33: Imdelltra - Recommended Concomitant Medications for Administration for Cycle 1
Table 5-34: Imdelltra - Recommended Dosage and Schedule
Table 5-35: Imdelltra - Recommendations for Restarting Therapy After Dosage Delay
Table 5-36: Imdelltra - Guidelines for Grading & Dosage Modification & Management of Cytokine Release Syndrome
Table 5-37: Imdelltra - Guidelines for Management of Neurologic Toxicity including Immune Effector Cell-Associated Neurotoxicity Syndrome
Table 5-38: Ordspono - Recommended dose
Table 5-39: Ordspono - Premedications & post-medications for patients with r/r FL or r/r DLBCL
Table 5-40: Ziihera - Dosage Modifications For Adverse Reactions
Table 5-41: Bizengri - Premedications Prior To Infusions
Table 5-42: Bizengri - Recommended Dosage Modifications & Management For Adverse Reactions
Table 5-43: Lynozyfic - Recommended Posology
List of Figures
Figure 2-1: Global - Multispecific Antibodies Sales (US$ Million), 2020-2025
Figure 2-2: Global - Market Sales by Multispecific Antibodies (US$ Million), Q1’2025
Figure 2-3: Global -Market Sales by Multispecific Antibodies (%), Q1’2025
Figure 2-4: Global - Market Sales by Multispecific Antibodies (US$ Million), 2024
Figure 2-5: Global -Market Sales by Multispecific Antibodies (%),2024
Figure 2-6: Global - Multispecific Antibodies Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 2-7: US - Multispecific Antibodies Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 2-8: ROW - Multispecific Antibodies Quarterly Sales (US$ Million), Q1-Q4’2024
Figure 2-9: Global - Multispecific Antibody Market Opportunity Assessment (US$ Billion), 2025 - 2030
Figure 2-10: Grabody I Platform - Mechanism of Action 1
Figure 2-11: Grabody I Platform - Mechanism of Action 2
Figure 2-12: Abz2 Bispecific Platform
Figure 2-13: Abz2 Bispecifics - Benefits
Figure 2-14: Neo-X-Prime Bispecific Mechanism
Figure 2-15: BiTE - Structure
Figure 2-16: BiTE Molecule
Figure 2-17: ADAPTIR Bispecific Structure
Figure 2-18: ADAPTIR-FLEX
Figure 2-19: BioAtla CABs - Features
Figure 2-20: BioAtla CABs - Benefits
Figure 2-21: FIT-Ig - Proprietary Bispecific Platform
Figure 2-22: 3-Step DuoBody Production Process
Figure 2-23: DuoHexaBody Molecules - Schematic
Figure 2-24: BEAT Platform - Multispecific Antibodies
Figure 2-25: IMBiologic Bispecific Antibodies - Strategy
Figure 2-26: IMBiologic Bispecific Antibodies - Mechanism of Action
Figure 2-27: ANKET® Platform - Innate Pharma
Figure 2-28: B-Body Bispecific Antibody - Structre
Figure 2-29: iTAb - Patented Structure
Figure 2-30: iTAb - Mechanism of Action
Figure 2-31: xLinkBsAb - Structure
Figure 2-32: Multiclonics - Distinctive Characteristics
Figure 2-33: Biclonics - Format
Figure 2-34: Merus - Triclonics Platform
Figure 2-35: STEALTH - ModeX Therapeutics
Figure 2-36: MSTAR - ModeX Therapeutics
Figure 2-37: MSTAR - Features
Figure 2-38: DARPin Platform - Molecular Partners
Figure 2-39: Novel HBICE
Figure 2-40: HBICE - Mechanism of Action 1
Figure 2-41: HBICE - Mechanism of Action 2
Figure 2-42: Numab Therapeutics - Technology
Figure 2-43: Phanes Therapeutics - PACbody Platform
Figure 2-44: Phanes Therapeutics - SPECpair Platform
Figure 2-45: Phanes Therapeutics - ATACCbody
Figure 2-46: Purple Biotech - Tribody Antibody Platform
Figure 2-47: PrecisionGATE Bispecific Antibody - Structure
Figure 2-48: Sanyou Super Trillion Common Light Chain Antibody Discovery Platform
Figure 2-49: GNC Antibodies - Sichuan Baili Pharmaceutical/SystImmune
Figure 2-50: Synimmune - Proprietary Bispecific Antibody Format
Figure 2-51: ALiCE - Characteristics
Figure 2-52: ALiCE - Schematic Diagram & Mechanism of Action
Figure 2-53: BiClone format
Figure 2-54: Zyngenia Technology Approach
Figure 3-1: Odronextamab (ELM-1) Phase I (NCT02290951) Study - Initiation & Completion Year
Figure 3-2: Odronextamab (ELM-1) Phase II (NCT03888105) Study - Initiation & Completion Year
Figure 3-3: Linvoseltamab (LINKER-MM1) Phase I/II (NCT03761108) Study - Initiation & Completion Year
Figure 3-4: PIT565 Phase I (NCT05397496) Study - Initiation & Completion Year
Figure 3-5: JNJ-79635322 Phase I (NCT05652335) Study - Initiation & Completion Year
Figure 3-6: GNC-038 Phase I/II (NCT05192486) Study - Initiation & Completion Year
Figure 3-7: GNC-038 Phase I/II (NCT05485753) Study - Initiation & Completion Year
Figure 3-8: IPH6501 Phase I/II (NCT06088654) Study - Initiation & Completion Year
Figure 3-9: AFM13 Phase I/II (NCT04074746) Study - Initiation & Completion Year
Figure 3-10: NM32-2668 Phase I (NCT06299163) Study - Initiation & Completion Year
Figure 3-11: GB263T Phase I/II (NCT05332574) Study - Initiation & Completion Year
Figure 3-12: GNC-039 Phase I (NCT04794972) Study - Initiation & Completion Year
Figure 3-13: Emicizumab (AHAEmi) Phase II (NCT05345197) Study - Initiation & Completion Year
Figure 3-14: Emicizumab Phase II/III (NCT06155955) Study - Initiation & Completion Year
Figure 3-15: Emicizumab (BCDI-XII) Phase I (NCT05500807) Study - Initiation & Completion Year
Figure 3-16: HMB-001 Phase I/II (NCT06211634) Study - Initiation & Completion Year
Figure 3-17: YBSW015 Early Phase I (NCT05369754) Study - Initiation & Completion Year
Figure 3-18: CLN-978 (CLN-978-SL-101) Phase I (NCT06613360) Study - Initiation & Completion Year
Figure 3-19: Vabysmo - Approval Year by Indication
Figure 3-20: Faricimab (MAGIC) Phase II (NCT05681884) Study - Initiation & Completion Year
Figure 3-21: Restoret (EYE103) - Tetravalent, Trispecific Antibody Binding Sites
Figure 3-22: Restoret (BRUNELLO) Phase II/III (NCT06571045) Study - Initiation & Completion Year
Figure 3-23: Restoret (BAROLO) Phase II/III (NCT06957080) Study - Initiation & Completion Year
Figure 4-1: US - Approved Multispecific Antibodies
Figure 4-2: EU - Approved Multispecific Antibodies
Figure 4-3: Japan - Approved Multispecific Antibodies
Figure 4-4: Chugai Pharmaceutical - Multispecific Antibody Clinical Pipeline
Figure 4-5: SAIL66 Phase I (NCT05735366) Study - Initiation & Completion Year
Figure 4-6: ONO-4685 (ONO-4685-05) Phase I (NCT06547528) Study - Initiation & Completion Year
Figure 4-7: ABL Bio - Bispecific Antibody Pipeline
Figure 4-8: ZW171 (ZWI-ZW171-101) Phase I (NCT06523803) Study - Initiation & Completion Year
Figure 5-1: Blincyto - Approval Year by Region
Figure 5-2: Blincyto - Patent Filing & Expiration Year
Figure 5-3: Blincyto - Treatment Regimen Cycles (Weeks)
Figure 5-4: Blincyto - Duration of Treatment Phase & Resting Phase in Induction & Consolidation Cycles for Treatment of MRD-Positive B-cell precursor (Days)
Figure 5-5: Blincyto - Recommended Number of Induction & Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL
Figure 5-6: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle & Full Treatment for Relapsed B-Cell Precursor ALL (Weeks)
Figure 5-7: Hemlibra - Approval Years by Region
Figure 5-8: Hemlibra - Cost per Unit & Supply of 30 mg/mL Subcutaneous Injection of Different Volumes (US$), May’2025
Figure 5-9: Hemlibra - Cost per Unit & Supply of 150 mg/mL Subcutaneous Injection of Different Volumes (US$), May’2025
Figure 5-10: Hemlibra - Recommended Loading & Maintenance Dose for Treatment of Hemophilia (mg/kg/Week)
Figure 5-11: Rybrevant - Price per Unit & Supply of Intravenous Solution (US$), May’2025
Figure 5-12: Rybrevant - Recommended Dose per Cycle by Body Weight (mg)
Figure 5-13: Rybrevant - Dose Reduction in Patients with Weight less than 80 kg (mg)
Figure 5-14: Rybrevant - Dose Reduction in Patients with Weight more than 80 Kg (mg)
Figure 5-15: Vabysmo - First Approval Year by Region
Figure 5-16: Vabysmo - Price per Unit & Supply of Intravitreal Solution (US$), May’2025
Figure 5-17: Lunsumio - Approval Years by Region
Figure 5-18: US - Price per Unit & Supply of Lunsumio Intravenous Solution (US$), May’2025
Figure 5-19: EU - Price per Unit & Supply of Lunsumio Intravenous Solution (US$), May’2025
Figure 5-20: Tecvayli - Approval Years by Region
Figure 5-21: Tecvayli - Patent Acceptance & Expiration Years
Figure 5-22: US - Cost per Unit & Supply of Tecvayli Subcutaneous Solution (US$), May’2025
Figure 5-23: EU - Cost per Unit & Supply of Tecvayli Subcutaneous Solution (US$), May’2025
Figure 5-24: Columvi - Approval Year by Region
Figure 5-25: US - Price per Unit & Supply of Columvi Intravenous Solution (US$), May’2025
Figure 5-26: EU - Price per Unit & Supply of Columvi Intravenous Solution (US$), May’2025
Figure 5-27: Epkinly - Approval Year by Region
Figure 5-28: US - Cost per Unit & Supply of Epkinly Subcutaneous Solution (US$), May’2025
Figure 5-29: EU - Cost per Unit & Supply of Epkinly Subcutaneous Solution (US$), May’2025
Figure 5-30: Talvey - Approval Year by Region
Figure 5-31: Talquetamab - FDA & EMA Designation Year
Figure 5-32: Talvey - Patent Acceptance & Expiration Year
Figure 5-33: US - Price per Unit & Supply of Talvey Intravenous Solution (US$), May’2025
Figure 5-34: EU - Price per Unit & Supply of Talvey Intravenous Solution (US$), February’2024
Figure 5-35: Elrexfio - Approval Years by Region
Figure 5-36: Elranatamab - FDA & EMA Designation Year
Figure 5-37: US - Price per Unit & Supply of Elrexfio Subcutaneous Solution (US$), May’2025
Figure 5-38: Imdelltra - Approval Years by Region
Figure 5-39: Imdelltra - Price per Unit & Supply of Intravenous Powder (US$), May’2025
Figure 5-40: US - Price Per Unit & Supply Of Ziihera (US$), May’2025
Figure 5-41: Zenocutuzumab - Active Patents
Figure 6-1: Global - Annual Blincyto Sales (US$ Million), 2020-2025
Figure 6-2: Regional - Blincyto Sales (US$ Million), Q1’2025
Figure 6-3: Regional - Blincyto Sales Quarterly (%), Q1’2025
Figure 6-4: Blincyto - Sales By Region (US$ Million), 2024
Figure 6-5: Blincyto - Sales By Region (%), 2024
Figure 6-6: US - Blincyto Sales ((US$ Million), 2020-2025
Figure 6-7: US - Blincyto Sales Quarterly (US$ Million), 2024
Figure 6-8: ROW - Blincyto Sales (US$ Million), 2020-2025
Figure 6-9: ROW - Blincyto Sales Quarterly (US$ Million), 2024
Figure 6-10: Global - Annual Hemlibra Sales (US$ Million), 2020-2024
Figure 6-11: Regional - US v/s ROW Sales (US$ Million), Q1’2025
Figure 6-12: Global - Hemlibra Sales by Region (US$ Million), Q1’2025
Figure 6-13: Global - Hemlibra Sales by Region (%), Q1’2025
Figure 6-14: Regional - US v/s ROW Sales (US$ Million), 2024
Figure 6-15: Global - Hemlibra Sales by Region (US$ Million), 2024
Figure 6-16: Global - Hemlibra Sales by Region (%),’2024
Figure 6-17: Global - Hemlibra Sales Quarterly (US$ Million), 2024
Figure 6-18: US - Annual Hemlibra Sales (US$ Million), 2020-2025
Figure 6-19: US - Hemlibra Sales Quarterly (US$ Million), 2024
Figure 6-20: Europe - Annual Hemlibra Sales (US$ Million), 2020-2025
Figure 6-21: Europe - Hemlibra Sales Quarterly (US$ Million), 2024
Figure 6-22: Japan - Annual Hemlibra Sales (US$ Million), 2020-2025
Figure 6-23: Japan - Hemlibra Sales Quarterly (US$ Million), 2024
Figure 6-24: ROW - Hemlibra Sales (US$ Million), 2020-2025
Figure 6-25: ROW - Hemlibra Sales Quarterly (US$ Million), 2024
Figure 6-26: Global - Annual Vabysmo Sales (US$ Million), 2022-2025
Figure 6-27: Global - Vabysmo US v/s ROW Sales (US$ Million), Q1’2025
Figure 6-28: Global - Vabysmo Sales by Region (US$ Million), Q1’2025
Figure 6-29: Global - Vabysmo Annual Sales by Region (%), Q1’2025
Figure 6-30: Global - Vabysmo US v/s ROW Sales (US$ Million), 2024
Figure 6-31: Global - Vabysmo Sales by Region (US$ Million), 2024
Figure 6-32: Global - Vabysmo Annual Sales by Region (%), 2024
Figure 6-33: Global - Vabysmo Sales Quarterly (US$ Million), 2024
Figure 6-34: US - Vabysmo Sales (US$ Million), 2022-2025
Figure 6-35: US - Vabysmo Sales Quarterly (US$ Million), 2024
Figure 6-36: Europe - Vabysmo Sales (US$ Million), 2022-2025
Figure 6-37: Europe - Vabysmo Sales Quarterly (US$ Million), 2024
Figure 6-38: Japan - Vabysmo Sales (US$ Million), 2022-2025
Figure 6-39: Japan - Vabysmo Sales Quarterly (US$ Million), 2024
Figure 6-40: ROW - Vabysmo Sales (US$ Million), 2022-2025
Figure 6-41: ROW - Vabysmo Sales Quarterly (US$ Million), 2024
Figure 6-42: Global - Annual Lunsumio Sales (US$ Million), 2022-2025
Figure 6-43: Global - Lunsumio US v/s ROW Sales (US$ Million), Q1’2025
Figure 6-44: Global - Lunsumio Sales by Region (US$ Million), Q1’2025
Figure 6-45: Global - Lunsumio Annual Sales by Region (%), Q1’2025
Figure 6-46: Global - Lunsumio US v/s ROW Sales (US$ Million), 2024
Figure 6-47: Global - Lunsumio Sales by Region (US$ Million), 2024
Figure 6-48: Global - Lunsumio Annual Sales by Region (%), 2024
Figure 6-49: Global - Lunsumio Sales Quarterly (US$ Million), 2024
Figure 6-50: US - Lunsumio Sales (US$ Million), 2022-2025
Figure 6-51: US - Lunsumio Sales Quarterly (US$ Million), 2024
Figure 6-52: Europe - Lunsumio Sales (US$ Million), 2022-2025
Figure 6-53: Europe - Lunsumio Sales Quarterly (US$ Million), 2024
Figure 6-54: ROW - Lunsumio Sales (US$ Million), 2022-2025
Figure 6-55: ROW - Lunsumio Sales Quarterly (US$ Million), 2024
Figure 6-56: Global - Tecvayli Sales (US$ Million), 2022-2025
Figure 6-57: Regional - Tecvayli Sales US$ Million), Q1’2025
Figure 6-58: Regional - Tecvayli Sales (%), Q1’2025
Figure 6-59: Global - Tecvayli Sales Quarterly (US$ Million), 2024
Figure 6-60: Regional - Tecvayli Sales (US$ Million), 2024
Figure 6-61: Regional - Tecvayli Sales (%), 2024
Figure 6-62: US - Tecvayli Sales (US$ Million), 2022-2025
Figure 6-63: US - Tecvayli Sales Quaterly (US$ Million), 2024
Figure 6-64: ROW - Tecvayli Sales (US$ Million), 2022-2025
Figure 6-65: ROW - Tecvayli Sales Quarterly (US$ Million), 2024
Figure 6-66: Global - Annual Columvi Sales (US$ Million), 2023-2025
Figure 6-67: Regional - US v/s ROW Sales (US$ Million), Q1’2025
Figure 6-68: Global - Columvi Sales by Region (US$ Million), Q1’2025
Figure 6-69: Global - Columvi Sales by Region (%), Q1’2025
Figure 6-70: Regional - US v/s ROW Sales (US$ Million), 2024
Figure 6-71: Global - Columvi Sales by Region (US$ Million), 2024
Figure 6-72: Global - Columvi Sales by Region (%),’2024
Figure 6-73: Global - Columvi Sales Quarterly (US$ Million), 2024
Figure 6-74: US - Annual Columvi Sales (US$ Million), 2023-2025
Figure 6-75: US - Columvi Sales Quarterly (US$ Million), 2024
Figure 6-76: Europe - Annual Columvi Sales (US$ Million), 2023-2025
Figure 6-77: Europe - Columvi Sales Quarterly (US$ Million), 2024
Figure 6-78: ROW - Columvi Sales (US$ Million), 2023-2025
Figure 6-79: ROW - Columvi Sales Quarterly (US$ Million), 2024
Figure 6-80: Global - Annual Epkinly Sales (US$ Million), 2023-2025
Figure 6-81: Global - Columvi Sales Quarterly Reported by AbbVie (US$ Million), 2024
Figure 6-82: US - Columvi Sales Quarterly Reported by AbbVie (US$ Million), 2024
Figure 6-83: ROW - Columvi Sales Quarterly Reported by AbbVie (US$ Million), 2024
Figure 6-84: Annual - Cadonilimab Sales (US$ Million), 2022-2024
Figure 6-85: Global - Annual Talvey Sales (US$ Million), 2025
Figure 6-86: Regional - Talvey Sales (US$ Million), Q1’2025
Figure 6-87: Regional - Talvey Sales Quarterly (%), Q1’2025
Figure 6-88: Global - Elrexfio Sales (US$ Million), 2023-2025
Figure 6-89: Global - Annual Elrexfio Sales (US$ Million), 2025
Figure 6-90: Regional - Elrexfio Sales (US$ Million), Q1’2025
Figure 6-91: Regional - Elrexfio Sales Quarterly (%), Q1’2025
Figure 6-92: US - Elrexfio Sales (US$ Million), 2023-2025
Figure 6-93: ROW - Elrexfio Sales (US$ Million), 2023-2025
Figure 6-94: Global - Imdelltra Sales (US$ Million), 2024-2025
Figure 6-95: Regional - Imdelltra Sales (US$ Million), Q1’2025
Figure 6-96: Regional - Imdelltra Sales Quarterly (%), Q1’2025
Figure 6-97: Global - Imdelltra Sales Quarterly (US$ Million), 2024
Figure 6-98: US - Imdelltra Sales (US$ Million), 2024-2025
Figure 6-99: US - Imdelltra Sales (US$ Million), 2024-2025
Figure 6-100: ROW - Imdelltra Sales (US$ Million), 2024-2025
Figure 6-101: Global - Ordspono Sales (US$ Million), 2022-2024
Figure 6-102: Global - Ordspono Sales Quarterly (US$ Million), 2024
Figure 6-103: Global - Ziihera Sales (US$ Million), 2024
Figure 7-1: Global - Multispecific Antibodies Clinical Trials by Phase (Numbers), 2025 till 2030
Figure 7-2: Global - Bispecific Antibodies Clinical Trials by Phase (Numbers), 2025 till 2030
Figure 7-3: Global - Tetraspecific Antibodies Clinical Trials By Phase (Number Of Antibodies), 2025 till 2030
Figure 7-4: Global - Trispecific Antibodies Clinical Trials by Phase, 2025 till 2030
